Digene Will Achieve Strategic Goals Faster Through Qiagen Merger, CEO Says
This article was originally published in The Gray Sheet
Executive Summary
Human papillomavirus test maker Digene will expand its international presence and gain critical mass to help counter looming competition in the lucrative HPV test market by merging with Dutch molecular diagnostics firm Qiagen
You may also be interested in...
Qiagen Buys DxS, Boasts "Deepest" Personalized Medicine Testing Pipeline
Qiagen is boasting the "deepest" pipeline of molecular diagnostics for personalized medicine after acquiring test maker DxS for $95 million, plus up to $35 million in milestone payments
Qiagen Buys DxS, Boasts "Deepest" Personalized Medicine Testing Pipeline
Qiagen is boasting the "deepest" pipeline of molecular diagnostics for personalized medicine after acquiring test maker DxS for $95 million, plus up to $35 million in milestone payments
Qiagen Monopoly In HPV Test Market Won’t Last, Judge Says
A U.S. district court turned down Third Wave Technologies' claims that Qiagen engages in anti-competitive behavior in the cervical cancer screening space, but the ruling suggests the direction of the market will be in Third Wave's favor